Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Organogenesis Holdings Inc (NASDAQ: ORGO) was $3.70 for the day, down -4.88% from the previous closing price of $3.89. In other words, the price has decreased by -$4.88 from its previous closing price. On the day, 1.11 million shares were traded. ORGO stock price reached its highest trading level at $4.105 during the session, while it also had its lowest trading level at $3.62.
Ratios:
Our analysis of ORGO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 112.26. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.69. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’25 when Driscoll Michael Joseph bought 25,000 shares for $5.08 per share.
Driscoll Michael Joseph sold 25,000 shares of ORGO for $127,535 on Mar 04 ’25. The Director now owns 166,879 shares after completing the transaction at $5.10 per share. On Dec 13 ’24, another insider, Gillheeney Gary S., who serves as the President and CEO of the company, sold 55,615 shares for $3.36 each. As a result, the insider received 186,866 and left with 3,044,779 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 469263616 and an Enterprise Value of 520675712. As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 660.71, and their Forward P/E ratio for the next fiscal year is 19.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.97 while its Price-to-Book (P/B) ratio in mrq is 1.77. Its current Enterprise Value per Revenue stands at 1.08 whereas that against EBITDA is 13.509.
Stock Price History:
The Beta on a monthly basis for ORGO is 1.81, which has changed by 0.2542373 over the last 52 weeks, in comparison to a change of -0.034466684 over the same period for the S&P500. Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.16. The 50-Day Moving Average of the stock is -13.63%, while the 200-Day Moving Average is calculated to be 9.45%.
Shares Statistics:
ORGO traded an average of 1.86M shares per day over the past three months and 1202180 shares per day over the past ten days. A total of 125.73M shares are outstanding, with a floating share count of 64.38M. Insiders hold about 49.24% of the company’s shares, while institutions hold 49.45% stake in the company. Shares short for ORGO as of 1741910400 were 8615328 with a Short Ratio of 4.62, compared to 1739491200 on 8666323. Therefore, it implies a Short% of Shares Outstanding of 8615328 and a Short% of Float of 28.78.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
